Double-Drug attack shows promise against rare sarcomas
NCT ID NCT03069378
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 28 times
Summary
This study tests whether combining a cancer-killing virus (T-VEC) with an immunotherapy drug (pembrolizumab) can shrink or control advanced sarcoma tumors. About 41 adults with metastatic or locally advanced sarcoma that cannot be surgically removed are participating. The main goal is to see how many patients experience significant tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Enable Medicine (Specimen Analysis Only)
Menlo Park, California, 94025, United States
-
MD Anderson Cancer Center (Data Analysis Only)
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, 10604, United States
-
Stanford University Medical Center
Stanford, California, 94305-5408, United States
Conditions
Explore the condition pages connected to this study.